Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 248 entries
View as:

Study on the Design and Application of Special Semi Recumbent Cushion for Postoperative Patients With Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05542680 Org: User:
Start: 09/30/22 End: 04/30/23 Due: 04/30/24

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Phase: N/A Priority: Normal
NCT ID: NCT06185400 Org: User:
Start: 02/01/24 End: 12/01/26 Due: 12/01/27

Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05747313 Org: User:
Start: 11/01/22 End: 12/31/23 Due: 12/31/24

Irinotecan, TAS-102 Plus Bevacizumab as a Third-Line or Beyond Therapy in mCRC Patients

Phase: N/A Priority: Normal
NCT ID: NCT06403709 Org: User:
Start: 08/01/22 End: 08/01/26 Due: 08/01/27

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06553365 Org: User:
Start: 08/15/24 End: 07/31/26 Due: 07/31/27

A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis

Phase: N/A Priority: Normal
NCT ID: NCT06048146 Org: User:
Start: 10/01/22 End: 09/01/29 Due: 09/01/30

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT07019337 Org: User:
Start: 06/30/25 End: 12/31/30 Due: 12/31/31

Multi-Centre, Observational Study on Safety of Bevacizumab Biosimilars in Clinical Practice Among Chinese Patients

Phase: N/A Priority: Normal
NCT ID: NCT05009017 Org: User:
Start: 01/01/21 End: 12/31/22 Due: 12/31/23

Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor

Phase: N/A Priority: Normal
NCT ID: NCT05749289 Org: User:
Start: 12/20/22 End: 12/20/25 Due: 12/20/26

Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06429839 Org: User:
Start: 03/01/23 End: 12/31/26 Due: 12/31/27

The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study

Phase: N/A Priority: Normal
NCT ID: NCT06958627 Org: User:
Start: 04/30/24 End: 04/30/27 Due: 04/30/28

Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06958614 Org: User:
Start: 09/02/19 End: 01/30/25 Due: 01/30/26

Application of Integrated Proteomic and Serum Metabolomic Analysis in Assessing the Efficacy and Prognosis of TACE Combined With Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06540508 Org: User:
Start: 02/01/23 End: 05/01/25 Due: 05/01/26

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Phase: N/A Priority: Normal
NCT ID: NCT02691871 Org: User:
Start: 02/29/16 End: 12/31/16 Due: 12/31/17

Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06757621 Org: User:
Start: 10/10/24 End: 11/01/32 Due: 11/01/33

A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）

Phase: N/A Priority: Normal
NCT ID: NCT03137368 Org: User:
Start: 08/09/18 End: 10/30/23 Due: 10/30/24

Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04821765 Org: User:
Start: 10/01/20 End: 12/31/24 Due: 12/31/25

Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Phase: N/A Priority: Normal
NCT ID: NCT06820320 Org: User:
Start: 02/15/25 End: 11/30/26 Due: 11/30/27

Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation

Phase: N/A Priority: Normal
NCT ID: NCT06405295 Org: User:
Start: 05/06/24 End: 05/01/29 Due: 05/01/30

Prognosis Stratification for pT4bN0M0 Colorectal Cancer Following Multivisceral Resection

Phase: N/A Priority: Normal
NCT ID: NCT06115837 Org: User:
Start: 09/01/23 End: 09/26/23 Due: 09/26/24

Surgery or Chemoradiotherapy for Cervical Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05327517 Org: User:
Start: 04/10/22 End: 12/31/28 Due: 12/31/29

Mitoxantrone Hydrochloride Liposome Combined With Capecitabine in Patients With HER-2 Negative Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06156761 Org: User:
Start: 11/28/23 End: 04/30/25 Due: 04/30/26

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06170697 Org: User:
Start: 03/01/23 End: 07/31/25 Due: 07/31/26

Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05497739 Org: User:
Start: 06/28/22 End: 06/20/24 Due: 06/20/25

Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.

Phase: N/A Priority: Normal
NCT ID: NCT06205472 Org: User:
Start: 01/26/24 End: 12/12/26 Due: 12/12/27